425: NLS Pharmaceutics Announces Positive Preclinical Results for Mazindol in Reducing Fentanyl-Induced Reward

NLS Pharmaceutics reports positive preclinical results from Study KO-943, demonstrating that Mazindol reduces fentanyl-induced reward in animal models, suggesting its potential as a non-opioid treatment for fentanyl use disorder.

Summary

• NLS Pharmaceutics announced positive results from a preclinical study (KO-943) evaluating Mazindol's efficacy in mitigating fentanyl-induced conditioned place preference (CPP) in mice.
• The study showed that Mazindol significantly reduced the rewarding effects of fentanyl in mice, suggesting its potential as a non-opioid treatment for fentanyl use disorder.
• The U.S. opioid and broader substance use disorder treatment market is projected to exceed $60 billion by 2029.
• Mazindol's mechanism of action involves partial mu-opioid receptor (MOP) agonism, serotonin 5-HT1A modulation, and orexin-2 receptor (OX2R) activity.
• The company recently raised up to $3 million and signed a $25 million committed equity facility agreement as part of the planned strategic merger with Kadimastem Ltd.

Sentiment

Score: 7

Explanation: The document presents positive preclinical results and strategic expansion plans, but the need for further clinical trials and regulatory approval introduces uncertainty.

Positives

• Mazindol demonstrated a significant reduction in fentanyl-induced reward in preclinical studies.
• Mazindol has a multi-target mechanism of action, potentially offering a safer alternative to opioid substitution therapies.
• The company is expanding its focus into the substance use disorder market, which is projected to grow significantly.
• Recent funding and a committed equity facility agreement provide financial resources for further development.

Negatives

• The results are from a preclinical study, and further clinical trials are needed to confirm efficacy in humans.
• The press release focuses on animal studies and does not provide information on human trials.

Risks

• Clinical trials may not replicate the positive results seen in preclinical studies.
• Regulatory approval may not be granted for Mazindol as a treatment for substance use disorders.
• Competition from existing and emerging therapies in the substance use disorder market.
• The merger with Kadimastem may not be completed or may not yield the expected benefits.

Future Outlook

NLS Pharmaceutics plans to continue developing Mazindol for substance use disorders and other CNS disorders, leveraging its unique pharmacological action. The company anticipates further development of Kadimastem's cell therapy clinical assets following the merger.

Management Comments

• Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics, stated that the data provide compelling evidence of Mazindol's multi-target potential to address the opioid crisis.
• Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics, believes the preclinical findings represent a significant milestone in their strategic expansion into substance use disorders.

Industry Context

The announcement addresses the urgent need for non-opioid treatments for fentanyl use disorder, aligning with national efforts to combat the opioid epidemic. The company is positioning Mazindol as a differentiated asset in the growing substance use disorder treatment market.

Comparison to Industry Standards

• Current opioid substitution therapies, like methadone and buprenorphine, are effective but carry a risk of dependence.
• Mazindol's multi-target mechanism of action, including partial mu-opioid receptor (MOP) modulation, 5-HT1A receptor interaction, and OX2R activity, is designed to reduce both opioid reward and withdrawal symptoms without the dependence risk associated with substitution therapies.
• Companies like Indivior and Alkermes are key players in the opioid addiction treatment market, offering products like Suboxone and Vivitrol, respectively.
• NLS Pharmaceutics aims to differentiate Mazindol by offering a non-opioid alternative with a unique mechanism of action.

Stakeholder Impact

• Positive results could benefit patients suffering from fentanyl use disorder by providing a non-opioid treatment option.
• Shareholders may see increased value if Mazindol progresses successfully through clinical trials and receives regulatory approval.
• The merger with Kadimastem could create synergies and enhance the combined company's pipeline.

Next Steps

• Further clinical trials to evaluate Mazindol's efficacy and safety in humans.
• Continued development of Mazindol for substance use disorders and other CNS disorders.
• Completion of the merger with Kadimastem Ltd.
• Development of Kadimastem's cell therapy clinical assets.

Key Dates

Keywords

Mazindol, NLS Pharmaceutics, Fentanyl, Opioid, Substance Use Disorder, Addiction, CNS Disorders, Preclinical Study, KO-943, Kadimastem, Merger